![Alexander Denner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alexander Denner
Director/Board Member at
IRONWOOD PHARMACEUTICALS, INC.
Net worth: 915 023 $ as of 31/05/2026
Profile
Alexander John Denner is a businessperson who founded Sarissa Capital Management LP and who has been the head of 6 different companies. Currently, Dr. Denner holds the position of Chairman & Chief Executive Officer of Sarissa Capital Acquisition Corp., Chief Executive Officer & Chief Investment Officer at Sarissa Capital Management LP and Chairman at The Medicines Co. Dr. Denner is also on the board of Biogen, Inc., Ironwood Pharmaceuticals, Inc. and Biogen GmbH. Dr. Denner previously was Portfolio Manager at Viking Global Investors LP, Non-Executive Chairman of Enzon Pharmaceuticals, Inc., Chairman of ARIAD Pharmaceuticals, Inc., Chairman for The Medicines Co., Senior Managing Director at Icahn Partners LP, Managing Director at Icahn Partners Master Fund LP, Senior Managing Director at Icahn Capital LP and Executive Director at Morgan Stanley Investment Management, Inc. Alexander John Denner received an undergraduate degree from Massachusetts Institute of Technology and a graduate degree and a doctorate from Yale University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/03/2026 | 256,309 ( 0.16% ) | 915 023 $ | 31/05/2026 |
Alexander Denner active positions
| Companies | Position | Start |
|---|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Director/Board Member | 09/11/2020 |
Biogen GmbH
 Biogen GmbH Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and supplies pharmaceutical products | Director/Board Member | 01/01/2009 |
Sarissa Capital Management LP
 Sarissa Capital Management LP Investment ManagersFinance Sarissa seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. They conduct rigorous, fundamentals-based research. Sarissa is an activist firm and is included in SharkWatch50 as one of the 50 most prominent and impactful activist investors. | Chief Executive Officer | 01/01/2012 |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Director/Board Member | 08/09/2021 |
Former positions of Alexander Denner
| Companies | Position | End |
|---|---|---|
| BIOGEN INC. | Director/Board Member | 26/06/2023 |
| SARISSA CAPITAL ACQUISITION CORP. | Chief Executive Officer | 01/12/2022 |
| THE MEDICINES COMPANY | Chairman | 01/04/2020 |
| BIOVERATIV INC | Director/Board Member | 08/03/2018 |
| ARIAD PHARMACEUTICALS, INC. | Chairman | 16/02/2017 |
Training of Alexander Denner
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
71
1st degree connections
25
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 25 |
|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Enzon Pharmaceuticals, Inc.
 Enzon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative therapeutics for cancer patients | Health Technology |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells drug products | Health Technology |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
VIVUS, Inc.
 VIVUS, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes next-generation therapies | Health Technology |
Viking Global Investors LP
 Viking Global Investors LP Investment ManagersFinance VGI is an active, long-term manager aiming to achieve maximum capital appreciation while mitigating general market risk by employing a hedged approach and taking short and long positions. The firm performs fundamental analysis to select investments primarily in public equity securities, but also in private equity and other financial instruments. They typically invest in companies located around the world that operate in a wide range of industries. | Finance |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for serious or life-threatening diseases with significant unmet needs | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Ironwood Pharmaceuticals, Inc.
 Ironwood Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets gastrointestinal products | Health Technology |
Morgan Stanley Investment Management, Inc.
 Morgan Stanley Investment Management, Inc. Investment ManagersFinance MSIM’s investment strategies span the risk/return spectrum across geographies, investment styles and asset classes, including equity, fixed income, alternatives and private markets. When considering their clients’ unique investment profiles, the firm applies a holistic approach, with a goal of incorporating the different factors affecting investors’ investment decisions. The firm combines top-down country allocation with bottom-up stock selection and disciplined risk management. | Finance |
Icahn Partners LP
 Icahn Partners LP Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Icahn Partners Master Fund LP
 Icahn Partners Master Fund LP Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Icahn Capital LP
 Icahn Capital LP Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Sarissa Capital Management LP
Sarissa Capital Management LP Investment ManagersFinance Sarissa seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. They conduct rigorous, fundamentals-based research. Sarissa is an activist firm and is included in SharkWatch50 as one of the 50 most prominent and impactful activist investors. | Finance |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
HyperMed, Inc.
 HyperMed, Inc. Medical DistributorsDistribution Services Develops medical imaging devices | Distribution Services |
Biogen GmbH
Biogen GmbH Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and supplies pharmaceutical products | Health Technology |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that engages in discovery, research, development and commercialization of therapies for hemophilia & blood disorders | Health Technology |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Health Technology |
Sarissa Capital Acquisition Corp.
 Sarissa Capital Acquisition Corp. Financial ConglomeratesFinance Operates as blank check company | Finance |
- Stock Market
- Insiders
- Alexander Denner
